Aruküla (EE)
{name}
{subtitle}
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~17 mi. (Tallinn, Estonia, +158 more cities)
facility
North Estonia Medical Centre Foundation ( Site 1601)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~17 mi. (Tallinn, Estonia, +122 more cities)
facility
SA Pohja-Eesti Regionaalhaigla ( Site 2201)
condition
Small Cell Lung Carcinoma
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~17 mi. (Tallinn, Estonia, +92 more cities)
facility
North Estonia Medical Centre Foundation ( Site 0081)
condition
Bladder Urothelial Carcinoma
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~75 mi. (Helsinki, Finland, +144 more cities)
facility
HYKS ( Site 1800)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type